<< Back to News

System Formulary Update
Brivaracetam (Briviact)

Situation:

Brivaracetam 50 mg/5 mL intravenous solution was approved for addition to the health system formulary at the System Pharmacy & Therapeutics Committee meeting.

Background:

The following medication was reviewed: Brivaracetam 50 mg/5 mL intravenous solution

Assessment/Recommendations:

System P&T voted to include Brivaracetam 50 mg/5 mL intravenous solution to the UNC Health Medication Formular with the following restrictions:

• Brivaracetam 50 mg/5 mL intravenous for patients with refractory status epilepticus who have failed levetiracetam AND one of the following:
  • Valproate acid, fosphenytoin or phenytoin, or lacosamide 
• use of IV formulation is limited to a maximum of 3 days, whereby the patients will transition to enteral formulations

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, September 24, 2024